A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2
- 23 May 2020
- journal article
- research article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 144, 109850
- https://doi.org/10.1016/j.mehy.2020.109850
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple SclerosisPLOS ONE, 2017
- The ratio of Th17/Treg cells as a risk indicator in early acute respiratory distress syndromeCritical Care, 2015
- Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseasesSwiss Medical Weekly, 2014
- T cell-mediated immune response to respiratory coronavirusesImmunologic Research, 2014
- Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow TransplantationSeminars in Oncology, 2012
- Excessive Neutrophils and Neutrophil Extracellular Traps Contribute to Acute Lung Injury of Influenza PneumonitisThe American Journal of Pathology, 2011
- Immunopathogenesis of coronavirus infections: implications for SARSNature Reviews Immunology, 2005
- Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS PatientsEmerging Infectious Diseases, 2004
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004
- Cyclophosphamide-Induced Immunological Tolerance: an OverviewImmunobiology, 1996